Physician profile
Jeeyoon Park
NPI 1033405840
$1,972.83
in general payments reported to CMS, 2019-2025
23 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $188 · 2021: $383 · 2022: $266 · 2023: $202 · 2024: $336 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $830.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.35 | 2019-2023 | |
| Avion Pharmaceuticals | $170.77 | 2019-2021 | |
| Myriad Women'S Health, INC. | $140.45 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $119.45 | 2019-2025 | Myosure Tissue Removal Device, Acessa Provu System, Aptima |
| Astellas Pharma US INC | $113.39 | 2024-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $102.41 | 2019-2025 | |
| Allergan, INC. | $92.07 | 2019-2020 | |
| Pfizer INC. | $91.45 | 2024-2025 | |
| Coopersurgical, INC. | $89.50 | 2019-2024 | Paragard T 380a |
| Organon LLC | $75.06 | 2022-2025 | Nexplanon |
| Seqirus USA INC | $54.06 | 2024-2025 | Fluad, Flucelvax |
| Exeltis, USA INC. | $42.56 | 2024 | Slynd |
| Sanofi Pasteur INC. | $38.48 | 2024 | |
| Aspira Women'S Health INC | $35.40 | 2021-2022 | |
| Dysis Medical, INC. | $35.10 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $30.36 | 2019 | |
| Daiichi Sankyo INC. | $27.41 | 2022 | |
| Mayne Pharma Commercial LLC | $24.19 | 2021 | |
| Therapeuticsmd, INC. | $23.85 | 2022 | |
| Biogen, INC. | $22.81 | 2025 | Zurzuvae |
| Amgen INC. | $14.85 | 2019 | |
| Channel Medsystems, INC. | $14.65 | 2023 | |
| Merck Sharp & Dohme LLC | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeeyoon Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.